Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2021-06-07 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于聘请公司2021年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the appointment of the company's audit firm for the 2021 fiscal year. It details the qualifications, experience, and independence of the audit firm, the approval process by the board and supervisory committee, and the audit fees. It does not contain any financial statements or audit results, nor is it a full audit report. The document is relatively short (3467 characters) and serves as a formal announcement of the audit firm appointment rather than the audit report itself. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit-related announcements excluding full annual reports. FY 2021
2021-06-07 Chinese
北京大成（广州）律师事务所关于康芝药业股份有限公司调整业绩承诺方案及签署相关补充协议暨关联交易的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of a performance commitment scheme and related supplementary agreements and related party transactions for a company. It discusses the background, legal compliance, and procedural steps related to the adjustment of performance commitments due to the impact of COVID-19. The document is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to corporate transactions and compliance. It does not contain financial statements or earnings data, nor is it a notice of voting results or a proxy statement. It is a legal proceedings related document providing legal opinions on a corporate matter. Therefore, the most appropriate classification is Legal Proceedings Report (LTR).
2021-06-07 Chinese
关于召开2020年度股东大会通知的公告
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2020 Annual General Meeting (AGM) of 康芝药业股份有限公司, including the date, location, voting procedures (both onsite and online), agenda items to be discussed and voted on, registration details, and proxy forms. It does not contain the actual annual report, financial statements, or voting results, but rather the announcement and information related to the upcoming AGM. The document length is about 5652 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2021-06-07 Chinese
独立董事关于第五届董事会第十五次会议相关事项的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent opinion statement from independent directors regarding the company's board meeting agenda items, including the appointment of the 2021 audit firm and opinions on performance commitments and related party transactions. It references audit reports and compliance with regulatory guidelines but does not contain full financial statements or detailed audit results itself. The document is short (1161 characters) and serves as a formal opinion or certification related to board matters rather than a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit firm appointment and audit-related opinions without being a full annual report or standalone audit report with financials. FY 2021
2021-06-07 Chinese
关于控股股东进行约定购回式证券交易暨持股比例变动超过1%的公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from a company regarding a change in shareholding by its controlling shareholder through a repurchase agreement transaction. It details the shareholding change exceeding 1%, the nature of the transaction, and compliance with relevant securities regulations. The document length is about 2990 characters, which is relatively short and focused on a specific shareholding change event. It does not contain financial statements, earnings data, or management discussion. It is not an annual or interim report, nor an earnings release or management report. The content fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. Therefore, the correct classification is MRQ with high confidence.
2021-06-03 Chinese
关于控股股东股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from 康芝药业股份有限公司 regarding the release of pledged shares by its controlling shareholder. It details the number of shares released from pledge, the shareholder's total shareholding and pledge status, and includes tables with shareholding data. There is no financial statement, earnings data, or management discussion. The document is a specific announcement about share pledge status, which fits the category of a Regulatory Filing (RNS) as it is a regulatory disclosure about share pledge changes and not a financial report or capital change announcement. The document length is short and focused on a specific shareholder pledge release event, not a full report or capital structure change like a share issue or buyback.
2021-06-03 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.